# Kangyuan Biomedical Tech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kangyuan-biomedical-tech

- Industry: Biotechnology
- Headquarters: Dalian, China
- Website: www.cmtdl.cn
- Latest round: Angel (Jun 4, 2024)
- Investors on record: 1

## About

Founded in 2016 and based in Dalian, China, Kangyuan Biomedical Tech is a biomedical technology company that focuses on the research and development of blood purification adsorption materials. In 2019, the company was approved by the National Development and Reform Commission's Northeast Revitalization Project. In 2021, it established a blood purification adsorption column product testing platform. In June 2024, the firm closed an angel funding. As of June 2024, Kangyuan Biomedical Tech has 54 employees. Lingyun Jia, the company's founder and chief scientist, is currently the dean of the School of Bioengineering at Dalian University of Technology, chairman of the Blood Purification Materials Branch of the Chinese Society of Biomaterials, etc.

The company's main products include cytokine series products and AAV adsorption fillers. AAV adsorption media include AAV broad-spectrum affinity chromatography media, affinity ligand detection kits and AAV capture kits. The company's products are used to treat renal failure, liver failure, and autoimmune diseases. It also provides customized nanobody services.

The company’s revenue is generated by providing blood purification adsorbent materials.

The company will use the angel funding for new product research and development, core technology improvement and product clinical trial promotion.

## Funding rounds

- Angel, Jun 4, 2024 — Dalton Venture

## Investors

- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Angel